Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

dimethylarginine

 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2019
Review
2019
Obesity and its comorbidities, including type 2 diabetes and cardiovascular disease, are straining our healthcare system… Expand
  • table 1
  • table 1
  • table 2
Is this relevant?
Review
2018
Review
2018
The incidence and prevalence of diabetes mellitus is rapidly increasing worldwide at an alarming rate. Type 2 diabetes mellitus… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
Review
2018
Review
2018
With decreasing kidney function, cardiovascular disease (CVD) and mineral bone disorders frequently emerge in patients with… Expand
  • table 1
  • figure 1
Is this relevant?
Review
2018
Review
2018
In this narrative review, the biological/biochemical impact (toxicity) of a large array of known individual uremic retention… Expand
  • figure 1
  • table 1
  • table 2
  • table 3
  • figure 2
Is this relevant?
Highly Cited
2002
Highly Cited
2002
Background—An endogenous inhibitor of nitric oxide synthase, asymmetric dimethylarginine (ADMA), is elevated in patients with… Expand
  • figure 1
  • figure 2
  • figure 4
  • figure 5
  • figure 3
Is this relevant?
Highly Cited
2002
Highly Cited
2002
Asymmetric dimethylarginine (ADMA), an endogenous inhibitor of nitric oxide synthase (NOS), may be related to reduced… Expand
Is this relevant?
Highly Cited
2001
Highly Cited
2001
Background—Hyperhomocysteinemia is a putative risk factor for cardiovascular disease, which also impairs endothelium-dependent… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 5
  • figure 4
Is this relevant?
Highly Cited
2001
Highly Cited
2001
Asymmetrical dimethylarginine (ADMA) is an endogenous nitric oxide synthase inhibitor, which has been suggested to be a novel… Expand
Is this relevant?
Highly Cited
1999
Highly Cited
1999
BACKGROUND Asymmetric dimethylarginine (ADMA) is an endogenous inhibitor of nitric oxide synthase (NOS). Plasma levels of ADMA… Expand
  • figure 1
  • figure 2
Is this relevant?
Highly Cited
1998
Highly Cited
1998
BACKGROUND Asymmetric dimethylarginine (ADMA) is an endogenous competitive inhibitor of nitric oxide (NO) synthase. Because… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?